Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of products targeting eye disease, cardiovascular disease, cancer, and inflammation. Marketed products include Eylea, Praluent, Dupixent, Libtayo, and Kevzara, with ongoing development collaborations involving monoclonal and bispecific antibodies, RNAi (Alnylam), and CRISPR-based gene editing (Intellia).